MannKind’s to advance inhaled clofazimine to phase 2/3 for lung disease

Scientific Research Performed by a Female Chemist


MannKind (NASDAQ:MNKD) said clofazimine inhalation suspension (MNKD 101) will advance to an adaptive phase 2/3 study.

In addition, the company noted that a paper was published in the American Society for Microbiology journal Antimicrobial Agents and Chemotherapy

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!